Cargando…

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma

BACKGROUND: The epidermal growth factor receptor (EGFR) is a primary target of molecular targeted therapy for lung adenocarcinoma (LUAD). The mechanisms that lead to epigenetic abnormalities of EGFR in LUAD are still unclear. The purpose of our study was to evaluate the abnormal methylation of EGFR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Zhanyu, Qin, Fanglu, Yuan, Liqiang, Wei, Jiangbo, Sun, Yu, Qin, Junqi, Deng, Kun, Zheng, Tiaozhan, Li, Shikang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383738/ https://www.ncbi.nlm.nih.gov/pubmed/34447695 http://dx.doi.org/10.3389/fonc.2021.691915

Ejemplares similares

Development of a gene signature associated with iron metabolism in lung adenocarcinoma
por: Qin, Junqi, et al.
Publicado: (2021)

A novel gene signature derived from the CXC subfamily of chemokine receptors predicts the prognosis and immune infiltration of patients with lung adenocarcinoma
por: Deng, Kun, et al.
Publicado: (2022)

Comprehensive analysis of angiogenesis subtype of squamous cell carcinoma
por: Qin, Fanglu, et al.
Publicado: (2021)

TAGAP expression influences CD4+ T cell differentiation, immune infiltration, and cytotoxicity in LUAD through the STAT pathway: implications for immunotherapy
por: Xu, Zhanyu, et al.
Publicado: (2023)

Circ‐IGF1R inhibits cell invasion and migration in non‐small cell lung cancer
por: Xu, Zhanyu, et al.
Publicado: (2020)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Effect of EGFR-TKIs combined with craniocerebral radiotherapy on the prognosis of EGFR-mutant lung adenocarcinoma patients with brain metastasis: A propensity-score matched analysis
por: Deng, Guangchuan, et al.
Publicado: (2023)

Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations
por: Nishimura, Toshihide, et al.
Publicado: (2020)

The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis
por: Zheng, Yi, et al.
Publicado: (2021)

Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
por: Li, Jie, et al.
Publicado: (2020)

Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival
por: Li, Hui, et al.
Publicado: (2023)

Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis
por: Xiao, Jian, et al.
Publicado: (2020)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

c-Src Increases the Sensitivity to TKIs in the EGFR-Mutant Lung Adenocarcinoma
por: Min, Weili, et al.
Publicado: (2021)

Role of GPER1 in the Mechanism of EGFR-TKIs Resistance in Lung Adenocarcinoma
por: Li, Zhenhua, et al.
Publicado: (2022)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Prognostic Role of Combined EGFR and Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma
por: Wongpattaraworakul, Wattawan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
por: Fu, Fangqiu, et al.
Publicado: (2021)

Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
por: Hong, Duo, et al.
Publicado: (2020)

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
por: Chen, Hongjin, et al.
Publicado: (2021)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report
por: Ye, Junru, et al.
Publicado: (2022)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
por: Li, Teng, et al.
Publicado: (2021)

Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2022)

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
por: Bai, Lu, et al.
Publicado: (2023)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

The efficacy of neoadjuvant EGFR-TKI therapy combined with radical surgery for stage IIIB lung adenocarcinoma harboring EGFR mutations: A retrospective analysis based on single center
por: Xiong, Yicheng, et al.
Publicado: (2023)

Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis
por: Chen, Xishan, et al.
Publicado: (2021)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Targeting EGFR in Esophagogastric Cancer
por: Maron, Steven B., et al.
Publicado: (2020)

Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival
por: Yang, Jing, et al.
Publicado: (2022)

Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients
por: Khiewngam, Khantong, et al.
Publicado: (2023)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Clinical Features and Surgical Treatment of Synchronous Multiple Primary Lung Adenocarcinomas With Different EGFR Mutations
por: Qu, Rirong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_23rk52lk500qefbobcfu80n1a2